-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CB-103 in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CB-103 in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CB-103 in T-Cell Acute Lymphocytic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CB-010 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CB-010 in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CB-010 in Follicular Lymphoma Drug Details: CB-010 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CB-010 in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CB-010 in Mantle Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CB-010 in Mantle Cell Lymphoma Drug Details: CB-010 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CB-010 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CB-010 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CB-010 in Diffuse Large B-Cell Lymphoma Drug Details: CB-010 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CB-010 in Primary Mediastinal B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CB-010 in Primary Mediastinal B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CB-010 in Primary Mediastinal B-Cell Lymphoma Drug Details: CB-010 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CB-010 in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CB-010 in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CB-010 in B-Cell Non-Hodgkin Lymphoma Drug Details: CB-010 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CB-307 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CB-307 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CB-307 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details:...
-
Sector Analysis
NewThe Masters Golf Tournment, 2024 – Post Event Analysis
An analysis of the recent 2024 Masters, including a look at its sponsorship portfolio, broadcasters, attendance and ticketing. The final round of the 2024 Masters averaged a 5.2 rating and 9.59 million viewers on CBS. CBS and ESPN shared the broadcasting rights to broadcast the 2024 Masters across the US. ESPN who broadcast the first two rounds of the 2024 Masters, averaged 3.4 million viewers for its two day coverage. The final round of the masters, played on Sunday April...
-
Sector Analysis
NewNCAA Basketball Championships 2024 – Event Analysis
An analysis of the recent 2024 NCAA Basketball Championships , including a look at its sponsorship portfolio, broadcasters, prize money, ticketing and attendance. CBS, which broadcasted the men’s title game has a 13-year agreement with the NCAA worth $771.43 million a year. According to Nielsen, the men’s title game between the University of Connecticut and Purdue University captured an audience of 14.82 million viewers. The women’s championship game between the University of South Carolina and the University of Iowa brought...